Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 8/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | SFRP1 | Q8N474 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989727 | 0.88 | DRD3 (0.53) | DRD3HRH3HTR6XIAPBIRC2 | |
| Hydrochloric Acid SCHEMBL4903398 | 0.87 | DRD3 (0.53) | DRD3HRH3HTR6XIAPBIRC2 | |
| SCHEMBL13989729 | 0.86 | DRD3 (0.55) | DRD3HRH3HTR6XIAPBIRC2 | |
| SCHEMBL13989656 | 0.85 | HTR6 (0.50) | DRD3HRH3HTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4890921 | 0.85 | DRD3 (0.54) | DRD3HRH3HTR6XIAPBIRC2 | |
| SCHEMBL13989724 | 0.85 | DRD3 (0.41) | DRD3HRH3HTR6XIAPBIRC2 | |
| Hydrochloric Acid SCHEMBL4898845 | 0.84 | HTR6 (0.49) | DRD3HRH3HTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4898857 | 0.84 | DRD3 (0.41) | DRD3HRH3HTR6XIAPBIRC2 | |
| SCHEMBL13989713 | 0.81 | HTR6 (0.47) | DRD3HRH3HTR6HTR2CHTR2B | |
| SCHEMBL4898750 | 0.81 | CHRM2 (0.43) | DRD3HRH3HTR6XIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| CN-101072768-A | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of CNS disorders | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | CN | disclosed |
| EP-1814873-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006038006-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR5A, TPH1 | DRD3 158/4885HRH3 257/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.